Baird Financial Group Inc. Buys 9,883 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Baird Financial Group Inc. increased its stake in Regeneron Pharmaceuticals by 28.5% during the 1st quarter, owning a total of 44,596 shares valued at approximately $28.28 million.
• Regeneron recently reported a quarterly earnings per share (EPS) of $12.89, significantly exceeding consensus estimates, and attributed a 3.6% year-over-year revenue growth with revenues of $3.68 billion.
• The company declared a quarterly dividend of $0.88 per share, resulting in an annualized dividend yield of 0.6%, with a current dividend payout ratio of 8.87%.

Baird Financial Group Inc. increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 28.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,596 shares of the biopharmaceutical company's stock after purchasing an additional 9,883 shares during the quarter. Baird Financial Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $28,284,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Activest Wealth Management grew its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 21 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Regeneron Pharmaceuticals by 11.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 398,236 shares of the biopharmaceutical company's stock worth $252,574,000 after acquiring an additional 41,826 shares during the period. Te Ahumairangi Investment Management Ltd acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $896,000. Trexquant Investment LP grew its holdings in Regeneron Pharmaceuticals by 0.5% during the 1st quarter. Trexquant Investment LP now owns 56,931 shares of the biopharmaceutical company's stock worth $36,107,000 after acquiring an additional 306 shares during the period. Finally, Landscape Capital Management L.L.C. acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $1,033,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Sanford C. Bernstein lifted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a report on Wednesday, August 27th. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Royal Bank Of Canada lifted their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a report on Monday, August 4th. Finally, Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Down 2.4%

NASDAQ REGN traded down $14.10 during trading hours on Wednesday, reaching $563.80. 1,118,266 shares of the company's stock were exchanged, compared to its average volume of 920,113. The company's 50-day moving average is $560.61 and its two-hundred day moving average is $586.09. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,182.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a market capitalization of $59.76 billion, a price-to-earnings ratio of 14.21, a price-to-earnings-growth ratio of 1.93 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the prior year, the business earned $11.56 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.